Archive for April, 2008

Immunotherapy and Sunitinib (Sutent) Investigation for Metastatic Renal Cell Carcinoma Opening at CORT

April 12, 2008

CORT has been chosen as an investigative site for a study of immunotherapy utilizing a primed autologous cellular vaccine in combination with standard sunitinib (Sutent) therapy for patients with metastatic renal cell carcinoma.  Patients who participate will have standard therapy with removal of the primary renal tumor, preparation of the cellular vaccine by harvest of peripheral blood cells by a simple procedure, and treatment with standard oral sunitinib therapy with delivery of the vaccine.  Patients will be followed for treatment response and long-term outcomes.

For more information about this study, visit the CORT website (, or call and speak with a study coordinator at 972-566-5588.